LOGIN  |  REGISTER
Recursion
Chimerix

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase

September 14, 2023 | Last Trade: US$28.60 0.07 0.25

ATLANTA, Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Gilmartin Group Emerging Growth Company Showcase on Thursday, September 21, 2023.  The Company's presentation is scheduled to begin at 11:00 a.m. ET.

A live webcast of the presentation will be accessible through Artivion's website, www.artivion.com, on the Investors page.  An archived copy of the webcast will be available for 90 days on the same website. 

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Artivion         

D. Ashley Lee                                                

Executive Vice President &

Chief Financial Officer

Phone: 770-419-3355

Gilmartin Group LLC

Brian Johnston / Lynn Lewis

Phone:  332-895-3222

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page